Investment
Features
FeesSafety
Academy
More
Pluang+

Compare S&P500 ETF (SPY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

S&P500 ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

S&P500 ETF vs Zimmer Biomet Holdings Inc — how do they compare? S&P500 ETF trades at $773.21, while Zimmer Biomet Holdings Inc trades at $96.48 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

SPYZBH
52-Week High
$773.22$107.71
52-Week Low
$631.99$79.58
Market Cap
$18.55B
Sector
Health
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

S&P500 ETF

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.

Zimmer Biomet Holdings Inc

ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.

The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH